22:16 , Aug 16, 2019 |  BioCentury  |  Finance

Chinese investment in U.S. biotechs to slow further

Chinese VCs say the slowing of investments into U.S. biotechs is likely to get worse before it gets better. In addition to continued CFIUS concerns and the ongoing trade war, capital inflows to Chinese life...
09:15 , Jul 9, 2019 |  BC Extra  |  Financial News

BioNTech broadens investor base with $325M B round

While BioNTech remains quiet about a timeline for a potential listing, the German biotech has further broadened its investor base with multiple Asia-Pacific firms backing a $325 million series B round as it invests in...
23:54 , Jun 28, 2019 |  BC Extra  |  Preclinical News

June 28 Preclinical Quick Takes: BioNTech targets pancreatitis; plus new targets for HIV and more

Anti-glycan mAb licensed by BioNTech could prevent pancreatitis  A Science study from Cold Spring Harbor Laboratory suggests the glycan CA19.9 (sialyl Lewis A), long known as a biomarker of pancreatic disease, actively drives the progression...
00:43 , Jun 18, 2019 |  BC Extra  |  Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint  VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs....
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
23:54 , May 8, 2019 |  BC Extra  |  Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

Takeda off-loads Xiidra, TachoSil  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) will sell Xiidra lifitegrast to Novartis AG (NYSE:NVS; SIX:NOVN) for $3.4 billion up front, plus $1.9 billion in milestones. Takeda said divesting the dry eye...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
20:49 , Mar 15, 2019 |  BioCentury  |  Finance

SNIPR targets the microbiome

SNIPR's strong IP position in prokaryotic CRISPR drew investors to a $50 million venture round led by Lundbeckfonden Emerge and LSP, the biggest series A yet for a CRISPR antibiotics and autoimmune company. Lundbeckfonden Emerge's...
20:07 , Mar 13, 2019 |  BC Extra  |  Financial News

BioNTech mum on $800M IPO report

Amid a report that it will seek an $800 million IPO, BioNTech told BioCentury it is still evaluating all financial options. Citing undisclosed people familiar with the IPO, Reuters has reported that BioNTech AG (Mainz,...
00:31 , Jan 25, 2019 |  BC Week In Review  |  Company News

BioNTech acquiring MAB Discovery's antibody generation unit

BioNTech AG (Mainz, Germany) will acquire the antibody generation unit of MAB Discovery GmbH (Neuried, Germany) to expand its capabilities to rapidly produce new mAb candidates. BioNTech will gain all of MAB Discovery's assets, employees...